The prognostic significance of anaplasia in childhood rhabdomyosarcoma: A report from the Children's Oncology Group.

[1]  R. Samstein,et al.  Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma , 2019, Clinical Cancer Research.

[2]  D. Rodeberg,et al.  Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group , 2019, Cancer medicine.

[3]  James R. Anderson,et al.  Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Khan,et al.  Targeted resequencing of pediatric rhabdomyosarcoma: report from the Children’s Oncology Group, the Children’s Cancer and Leukaemia Group, The Institute of Cancer Research UK, and the National Cancer Institute. , 2018 .

[5]  James R. Anderson,et al.  Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Wagers,et al.  Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers , 2014, Cancer.

[7]  James R. Anderson,et al.  PAX‐FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report , 2013, Pediatric blood & cancer.

[8]  James R. Anderson,et al.  Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2013, American journal of clinical pathology.

[9]  S. Spunt,et al.  Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas , 2013, Pediatric blood & cancer.

[10]  James R. Anderson,et al.  Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's O , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  James R. Anderson,et al.  Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Pappo,et al.  Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma , 2008, Cancer.

[13]  P. Winkler,et al.  Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Houghton,et al.  Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  James R. Anderson,et al.  Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Carli,et al.  European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Sorensen,et al.  Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes , 2002, Genes, chromosomes & cancer.

[18]  P. Sorensen,et al.  Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: An Intergroup Rhabdomyosarcoma Study , 2000, Genes, chromosomes & cancer.

[19]  James R. Anderson,et al.  Pretreatment TNM staging of childhood rhabdomyosarcoma , 1997, Cancer.

[20]  N. Breslow,et al.  Focal versus diffuse anaplasia in Wilms tumor--new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. , 1996, The American journal of surgical pathology.

[21]  L. Asmar,et al.  Childhood Rhabdomyosarocoma with Anaplastic (Pleomorphic) Features: A Report of the Intergroup Rhabdomyosarcoma Study , 1993, The American journal of surgical pathology.

[22]  H K Hawkins,et al.  Rhabdomyosarcoma in Children: Correlation of Form and Prognosis in One Institution's Experience , 1987, The American journal of surgical pathology.

[23]  博之 伊藤,et al.  急激に発生した篩骨洞 rhabdomyosarcoma 症例 , 1979 .